Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

In the randomized, placebo‐controlled, double‐blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Bone Miner Res
Asıl Yazarlar: Leder, Benjamin Z, Zapalowski, Carol, Hu, Ming‐Yi, Hattersley, Gary, Lane, Nancy E, Singer, Andrea J, Dore, Robin K
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916366/
https://ncbi.nlm.nih.gov/pubmed/31411768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.3848
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller